TriSalus Life Sciences shares are trading higher after the company announced CMS reimbursement for the TriNav Infusion System through the assignment of a New Technology Healthcare Common Procedure Coding System code.
Portfolio Pulse from Benzinga Newsdesk
TriSalus Life Sciences' stock price has increased following the announcement that the Centers for Medicare & Medicaid Services (CMS) will provide reimbursement for its TriNav Infusion System, which has been assigned a New Technology Healthcare Common Procedure Coding System (HCPCS) code.
December 14, 2023 | 5:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TriSalus Life Sciences' shares are up after CMS assigned a New Technology HCPCS code for reimbursement of its TriNav Infusion System.
The assignment of a New Technology HCPCS code by CMS for the TriNav Infusion System is a significant positive development for TriSalus Life Sciences. It means that the product will be eligible for reimbursement, which is likely to increase its adoption and usage. This can lead to higher revenues for the company, and as a result, investors are reacting positively to the news, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100